BioCryst Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
At the Bank of America Merrill Lynch conference. It's my pleasure to introduce our next company, BioCryst Pharmaceuticals. Presenting for BioCryst today is John Bluth, who is Head of Investor Relations. He's going to go through the slides and give you a brief overview of the company and upcoming catalysts. So I'll turn it over to you, John.
Thanks very much, Tazeen, and thanks to Bank of America Merrill Lynch for having us here today. I will be making some forward-looking statements over the course of the presentation. So please do refer to those in our SEC documents.
So BioCryst is a company that is focused on developing oral medicines for rare diseases, and our pipeline consists of mostly homegrown oral medicines for rare diseases. Our lead compound is an oral drug for hereditary angioedema, which is a hereditary condition that is very painful for patients that have it. They get unpredictable attacks of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
